Identification of factors associated with drug-therapy resistance by pheripheral blood serum cell-free nucleotic acids

2016 Fiscal Year Final Research Report

• Project/Area Number: 26670695
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Akita University
• Principal Investigator: Habuchi Tomonori 秋田大学, 医学(系)研究科(研究院), 教授 (00293861)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 腎癌 / 膀胱癌 / エキソソーム / 分子標的薬 / 液性生検 / PAI-1 / miR-21

Outline of Final Research Achievements

To explore candidate serum cell-free nucleotic acid or protein biomarkers associated with drug resistance in advanced urological cancers, we collected and analyzed the serum exosome RNA and proteins. As the results focusing on Axitinib therapy in advanced RCC patients, patients whose serum miR-21 level was decreased after Axitinib treatment had significantly better progression free survival. Patients whose serum PAI-1 level was decreased after Axitinib treatment had significantly better progression free survival and overall survival. In addition, the pre-treatment PAI-l level was significantly associated with the objective response rate.
In conclusion, the serum miR-21 level or PAI-1 protein level may be a promising biomarker in the Axitinib treatment for advanced RCC patients.

Free Research Field

泌尿器科